The guiding principle of arterial hypertension treatment, an omnipresent and current preventable causal factor, is the reduction of total mortality. We often forget that stroke is the third leading cause of death for women in the United States of America and the leading cause of incapacitation (5). Beside traditional risk factors for target organ damage that are the same for men and women (arterial hypertension, hyperlipidemia, diabetes, cigarette smoking, atrial fibrillation), there are also specific risk factors present only in women (differences in sex hormones, estrogen supplementation therapy, and pregnancy) (5).

Cardiovascular diseases (CVD) are responsible for more than 17 million cases of death per year (6). The overall data show that more women than men die of CVD. This group of diseases is responsible for 45% of all deaths in women and 38% of all deaths in men. In 2013, the World Health Organization published findings showing that arterial hypertension is responsible for at least 45% of cases of death due to heart disease and 51% cases of death due to stroke, and that every tenth person also has chronic kidney disease (CKD) (6). The risk of development of CKD in women is higher than in men (14% vs. 12%) (7). Chronic kidney disease affects approximately 195 million women worldwide and is the 8^th leading cause of death in women annually, with 600 000 cases of death (8). Female sex, arterial hypertension, advanced age, and obesity are characteristic for heart failure with preserved ejection fraction (HFpEF) (5, 9). In everyday practice, patients with heart remodeling due to hypertension with atrial fibrillation are common and require adjustment of oral doses of anticoagulation medication depending on the level of CKD, with an increasing prevalence of women of advanced age among them (10). Additionally, HFpEF is often inadequately recognized and managed, and it is associated with numerous comorbid states such as hypertension (60%-80%), ischemic heart disease (35%-70%), diabetes (20%-45%), and atrial fibrillation (15%-40%) (11).

Consequently, there have been efforts to raise awareness of the association between CKD, cardiovascular morbidity and mortality, and the possibility of preventive measures recommended by various societies, such as the formation of the Council on Kidney in Cardiovascular Disease as part of the American Heart Association, which approaches the issues of kidney disease as a part of translational medicine with the goal of reducing cardiovascular risk.

The prevalence of obesity in Europe is between 4-28% in men and 6.2%-36.5% in women. It is incredible that obesity is more common in women than in men. The prevalence of obesity increased with age (25% of persons between 45 and 72 years of age are overweight). What is worrying is the high prevalence of obesity in younger age groups, especially in childhood (8.8%). It is a well-known fact that cardiovascular mortality and morbidity as well as association with uncontrolled hypertension is higher in obese patients (2).

The specific characteristic of disorders related to obesity is the mechanism of insulin resistance and ectopic lipid accumulation, which contributes to organ damage in the context of metabolic diseases, indicating that kidney disease associated with obesity is really a state of lipodystrophy and aging process acceleration. The association between lipid-disordered metabolism, insulin resistance, and the activation of inflammatory processes leads to the development of glomerulopathy associated with obesity and heart and vascular remodeling (2). Hypertensive disorders have been recognized as an important risk factor for CVD in women (12).

It is important to differentiate between several specific states:

Taking oral contraceptives is associated with a small but significant increase in blood pressure (BP) and hypertension in 5% of women receiving oral contraceptive therapy (especially at older ages) (13). The incidence of myocardial infarction and ischemic stroke is low in the age group of women using oral contraceptives. Guidelines do not recommend the use of oral contraceptives in women who have uncontrolled hypertension, and the risk of developing hypertension is reduced with the cessation of oral contraceptives (14).

There is a low probability of BP rise in menopausal hypertensive women receiving hormone replacement therapy (15). Hormone replacement therapy and selective estrogen receptor modulators are not recommended for primary and secondary prevention of CVD.

There are no specific guidelines for the treatment of arterial hypertension in women except in pregnancy. The ESH/ESC guidelines for the treatment of hypertension from 2013 recommend commencing antihypertensive treatment at BP values >140/90 mmHg in women with gestational diabetes, preexisting hypertension with the manifestation of gestational diabetes, and in those with hypertension with asymptomatic organ damage or symptoms in any period of the pregnancy (14). The choice of medication for the treatment of hypertension in pregnancy are methyldopa, labetalol, and nifedipine (long-acting). In emergencies such as severe preeclampsia, the medication of choice is the intravenous application of labetalol (14). In women with preeclampsia, the risk of developing hypertension in older age is four times higher in comparison with women who did not have preeclampsia (16). The newest literature lists preeclampsia as an early marker of CVD risk. Women who had preeclampsia have double the risk of developing ischemic heart disease, stroke, and thromboembolic diseases in a period of 5-15 years after pregnancy (17). Complication associated with pregnancy also increase the risk of kidney disease. Preeclampsia, septic abortion, and inflammatory conditions such as acute or chronic pyelonephritis and autoimmune diseases such as lupus nephritis typically manifest in women and are the leading cause of acute kidney damage in women (4).

Chronic kidney disease, which is currently reaching increasingly pandemic proportions, is an additional risk factor for reduced fertility and unwanted outcomes in pregnancy, and women with CKD are at increased risk of poor outcomes due to greatly increased incidence of hypertension and preterm births (18). The progression of CKD in women, in addition to numerous disorders of other bodily systems, also leads to menstruation disorders, infertility, and early menopause. Women with premature menopause are at higher risk of developing CKD (19).

It is important to note that women are far less represented in a number of cardiovascular studies, especially those related to guidelines (20), which begs the question whether the existing guidelines are adequate for the treatment of women, or only for the treatment of men. Women die more often from CVD than men, and the risk of CKD in women is higher than in men. Even in the early stages, CKD has increased cardiovascular risk, and CVD is basically endothelial dysfunction with simultaneous changes in renal and coronary microcirculation. Further studies are needed to contribute to a better understanding of the unique characteristics related to female health, which have an additional influence on the safety and effectiveness of the treatment options being applied.